345 related articles for article (PubMed ID: 23588585)
1. Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.
Ting H; Deep G; Agarwal R
AAPS J; 2013 Jul; 15(3):707-16. PubMed ID: 23588585
[TBL] [Abstract][Full Text] [Related]
2. Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.
Raina K; Rajamanickam S; Singh RP; Deep G; Chittezhath M; Agarwal R
Cancer Res; 2008 Aug; 68(16):6822-30. PubMed ID: 18701508
[TBL] [Abstract][Full Text] [Related]
3. Silibinin prevents prostate cancer cell-mediated differentiation of naïve fibroblasts into cancer-associated fibroblast phenotype by targeting TGF β2.
Ting HJ; Deep G; Jain AK; Cimic A; Sirintrapun J; Romero LM; Cramer SD; Agarwal C; Agarwal R
Mol Carcinog; 2015 Sep; 54(9):730-41. PubMed ID: 24615813
[TBL] [Abstract][Full Text] [Related]
4. Silibinin--a promising new treatment for cancer.
Cheung CW; Gibbons N; Johnson DW; Nicol DL
Anticancer Agents Med Chem; 2010 Mar; 10(3):186-95. PubMed ID: 20015009
[TBL] [Abstract][Full Text] [Related]
5. Gram-scale purification of flavonolignan diastereoisomers from Silybum marianum (Milk Thistle) extract in support of preclinical in vivo studies for prostate cancer chemoprevention.
Graf TN; Wani MC; Agarwal R; Kroll DJ; Oberlies NH
Planta Med; 2007 Nov; 73(14):1495-501. PubMed ID: 17948171
[TBL] [Abstract][Full Text] [Related]
6. A cancer chemopreventive agent silibinin, targets mitogenic and survival signaling in prostate cancer.
Singh RP; Agarwal R
Mutat Res; 2004 Nov; 555(1-2):21-32. PubMed ID: 15476849
[TBL] [Abstract][Full Text] [Related]
7. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer.
Flaig TW; Glodé M; Gustafson D; van Bokhoven A; Tao Y; Wilson S; Su LJ; Li Y; Harrison G; Agarwal R; Crawford ED; Lucia MS; Pollak M
Prostate; 2010 Jun; 70(8):848-55. PubMed ID: 20127732
[TBL] [Abstract][Full Text] [Related]
8. Silymarin and Its Role in Chronic Diseases.
Neha ; Jaggi AS; Singh N
Adv Exp Med Biol; 2016; 929():25-44. PubMed ID: 27771919
[TBL] [Abstract][Full Text] [Related]
9. Silibinin, a natural flavonoid, modulates the early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis.
Kauntz H; Bousserouel S; Gosse F; Marescaux J; Raul F
Int J Oncol; 2012 Sep; 41(3):849-54. PubMed ID: 22735354
[TBL] [Abstract][Full Text] [Related]
10. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer.
Deep G; Agarwal R
Cancer Metastasis Rev; 2010 Sep; 29(3):447-63. PubMed ID: 20714788
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer prevention by silibinin.
Singh RP; Agarwal R
Curr Cancer Drug Targets; 2004 Feb; 4(1):1-11. PubMed ID: 14965263
[TBL] [Abstract][Full Text] [Related]
12. Targeting silibinin in the antiproliferative pathway.
Li L; Zeng J; Gao Y; He D
Expert Opin Investig Drugs; 2010 Feb; 19(2):243-55. PubMed ID: 20047507
[TBL] [Abstract][Full Text] [Related]
13. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.
Davis-Searles PR; Nakanishi Y; Kim NC; Graf TN; Oberlies NH; Wani MC; Wall ME; Agarwal R; Kroll DJ
Cancer Res; 2005 May; 65(10):4448-57. PubMed ID: 15899838
[TBL] [Abstract][Full Text] [Related]
14. Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.
Cufí S; Bonavia R; Vazquez-Martin A; Corominas-Faja B; Oliveras-Ferraros C; Cuyàs E; Martin-Castillo B; Barrajón-Catalán E; Visa J; Segura-Carretero A; Bosch-Barrera J; Joven J; Micol V; Menendez JA
Food Chem Toxicol; 2013 Oct; 60():360-8. PubMed ID: 23916468
[TBL] [Abstract][Full Text] [Related]
15. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations.
Brantley SJ; Oberlies NH; Kroll DJ; Paine MF
J Pharmacol Exp Ther; 2010 Mar; 332(3):1081-7. PubMed ID: 19934397
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin.
Bhatia N; Zhao J; Wolf DM; Agarwal R
Cancer Lett; 1999 Dec; 147(1-2):77-84. PubMed ID: 10660092
[TBL] [Abstract][Full Text] [Related]
17. Silybin and silymarin--new and emerging applications in medicine.
Gazák R; Walterová D; Kren V
Curr Med Chem; 2007; 14(3):315-38. PubMed ID: 17305535
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.
Tyagi A; Bhatia N; Condon MS; Bosland MC; Agarwal C; Agarwal R
Prostate; 2002 Nov; 53(3):211-7. PubMed ID: 12386921
[TBL] [Abstract][Full Text] [Related]
19. Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression.
Wu KJ; Zeng J; Zhu GD; Zhang LL; Zhang D; Li L; Fan JH; Wang XY; He DL
Acta Pharmacol Sin; 2009 Aug; 30(8):1162-8. PubMed ID: 19578386
[TBL] [Abstract][Full Text] [Related]
20. Silymarin and hepatocellular carcinoma: a systematic, comprehensive, and critical review.
Mastron JK; Siveen KS; Sethi G; Bishayee A
Anticancer Drugs; 2015 Jun; 26(5):475-86. PubMed ID: 25603021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
